Thermo Fisher Scientific reported a 10% revenue increase in Q2 2026, driven by 5% organic growth and improved margins. The company’s Pharma and Biotech sectors showed mid-single-digit gains, reflecting a market rebound. Recent acquisitions of Clario and Solventum’s Filtration and Separation business have expanded Thermo Fisher’s capabilities, enhancing customer spending share and revenue synergies. With reasonable valuation and expected 9-10% EPS growth, the stock presents an attractive risk/reward profile for investors.
Toncoin, now trading as Gram (GRAM), is priced at $1.3260, down 62.5% from its 12-month high of $3.5328. The price sits below key moving averages, indicating a bearish trend with no clear technical buy signals. Trading volume is significantly lower t...
A former Ripple engineer known as Bias Goose has revealed plans for a secret startup built on the XRP Ledger, centered around the RLUSD stablecoin. The project aims to integrate real-world business on-chain and promises higher yields than U.S. Treasu...
Ituran Location and Control Ltd. reported record revenue, profitability, and cash flow in Q2, driven by recurring revenue now making up 76% of total income. The company trades at reasonable valuations with potential 27% upside if growth and margins c...
InterContinental Hotels Group (IHG) reported strong first half 2026 results, with adjusted EBITDA up 9% and EPS up 13%, both outpacing revenue growth due to margin expansion. The company benefits from a robust pipeline of new rooms, representing 33% ...
Artificial intelligence workloads are accelerating US electricity demand growth by a decade, driving increased interest in nuclear power as a reliable energy source. The Department of Energy forecasts data centers will consume up to 12% of US electri...
